Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin. 72(1):7–33

Article  Google Scholar 

Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71(3):209–249

Article  Google Scholar 

Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin. 71(1):7–33

Article  Google Scholar 

Auchus RJ, Sharifi N (2020) Sex hormones and prostate cancer. Annu Rev Med. 71:33–45

Article  CAS  Google Scholar 

Chatalic KL, Konijnenberg M, Nonnekens J et al (2016) In vivo stabilization of a gastrin-releasing peptide receptor antagonist enhances PET imaging and radionuclide therapy of prostate cancer in preclinical studies. Theranostics. 6(1):104–117

Article  CAS  Google Scholar 

Tsechelidis I, Vrachimis A (2022) PSMA PET in imaging prostate cancer. Front Oncol. 12:831429

Article  Google Scholar 

Barve A, Jin W, Cheng K (2014) Prostate cancer relevant antigens and enzymes for targeted drug delivery. J Control Release. 187:118–132

Article  CAS  Google Scholar 

Kiess AP, Banerjee SR, Mease RC et al (2015) Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging. 59(3):241–268

CAS  Google Scholar 

Perera M, Papa N, Roberts M et al (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 77(4):403–417

Article  Google Scholar 

Maurer T, Eiber M, Schwaiger M, Gschwend JE (2016) Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 13(4):226–235

Article  CAS  Google Scholar 

Jeitner TM, Babich JW, Kelly JM (2022) Advances in PSMA theranostics. Transl Oncol. 22:101450

Article  CAS  Google Scholar 

Chen H, Cai P, Feng Y et al (2021) In vitro and in vivo comparative study of a novel 68Ga-labeled PSMA-targeted inhibitor and 68Ga-PSMA-11. Sci Rep. 11:19122

Article  CAS  Google Scholar 

Chang SS, Reuter VE, Heston WD et al (1999) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59(13):3192–3198

CAS  Google Scholar 

Chang SS (2004) Overview of prostate-specific membrane antigen. Rev Urol. 6(Suppl 10):S13–S18

Google Scholar 

Zhou J, Neale JH, Pomper MG, Kozikowski AP (2005) NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov. 4(12):1015–1026

Article  CAS  Google Scholar 

Okarvi SM (2019) Recent developments of prostate-specific membrane antigen (PSMA)-specific radiopharmaceuticals for precise imaging and therapy of prostate cancer: an overview. Clin Transl Imaging. 7(3):189–208

Article  Google Scholar 

Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 3(1):81–85

CAS  Google Scholar 

Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 82(11):2256–2261

Article  CAS  Google Scholar 

Eder M, Eisenhut M, Babich J, Haberkorn U (2013) PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging. 40(6):819–823

Article  Google Scholar 

Mesters JR, Barinka C, Li W et al (2006) Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J. 25(6):1375–1384

Article  CAS  Google Scholar 

Barinka C, Hlouchova K, Rovenska M et al (2008) Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs. J of Mol Bio 376(5):1438–1450

Article  CAS  Google Scholar 

Barinka C, Starkova J, Konvalinka J, Lubkowski J (2007) A high-resolution structure of ligand-free human glutamate carboxypeptidase II. Acta Crystallographica Section F-Struc Bio Com 63:150–153

Article  CAS  Google Scholar 

Barinka C, Byun Y, Dusich CL et al (2008) Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem. 51(24):7737–7743

Article  CAS  Google Scholar 

Neels OC, Kopka K, Liolios C, Afshar-Oromieh A (2021) Radiolabeled PSMA inhibitors. Cancers (Basel). 13(24)

Pastorino S, Riondato M, Uccelli L et al (2020) Toward the discovery and development of PSMA targeted inhibitors for nuclear medicine applications. Curr Radiopharm. 13(1):63–79

Article  CAS  Google Scholar 

Chen Y, Foss CA, Byun Y et al (2008) Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem. 51(24):7933–7943

Article  CAS  Google Scholar 

Maresca KP, Hillier SM, Femia FJ et al (2009) A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 52(2):347–357

Article  CAS  Google Scholar 

Banerjee SR, Kumar V, Lisok A et al (2019) 177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy. Eur J Nucl Med Mol Imaging. 46(12):2545–2557

Article  CAS  Google Scholar 

Kwon H, Lim H, Ha H et al (2020) Structure-activity relationship studies of prostate-specific membrane antigen (PSMA) inhibitors derived from alpha-amino acid with (S)- or (R)-configuration at P1′ region. Bioorg Chem. 104:104304

Article  CAS  Google Scholar 

Plechanovova A, Byun Y, Alquicer G et al (2011) (2011) Novel substrate-based inhibitors of human glutamate carboxypeptidase II with enhanced lipophilicity. J Med Chem. 54(21):7535–7546

Article  CAS  Google Scholar